AI Governance

Utah announced three planned health-care AI pilots yesterday, pairing a broader testing program with independent evaluation and clinical advisory involvement. The pilots cover acne telehealth, pelvic-health therapy and selected prescription renewals. Each requires state approval before launch. This is a concrete expansion of supervised experimentation, not general permission for autonomous clinical practice. Elsewhere, federal coverage continued to clarify advisory authority and disputed auditor selection, while enterprise reporting exposed a different problem: responsibility for AI failures can sit with teams that do not control purchasing.

• The important distinction in evaluation is not simply whether an outsider participates, but what that evaluator can examine and how findings affect decisions. Utah retains approval authority and requires evaluation data. The federal auditor debate, by contrast, has not established a finalized selection framework. Both make evaluator competence and mandate consequential, but they are not equivalent oversight arrangements.
• Enterprise accountability problems extend beyond technical controls. Recent briefings highlighted gaps in traceable approval and access boundaries; the Thoughtworks findings add purchasing authority to that picture. A team can be expected to answer for failures without having sufficient influence over the decisions that create exposure.